Year archive

Ascentage Pharma Group International — 2025 filings

All 58 regulatory filings released by Ascentage Pharma Group International (6855) in 2025, sourced directly from the official regulator.

58 Filings

2025 Period

2025 filings (58)

Filing	Released	Lang
List of directors and their roles and functions Board/Management Information	2025-12-30	English
(1) CHANGE IN COMPOSITION OF NOMINATION COMMITTEE; (2) APPOINTMENT OF LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR; (3) ESTABLISHMENT OF RESEARCH AND DEVELOPMENT COMMITTEE; AND (4) SUPPLEMEN Board/Management Information	2025-12-30	English
Voluntary Announcement - Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA Regulatory Filings	2025-12-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025 Regulatory Filings	2025-12-04	English
FURTHER GRANT OF AWARDS UNDER THE 2022 RSU SCHEME; AND GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION SCHEME Share Issue/Capital Change	2025-11-27	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025 Regulatory Filings	2025-11-06	English
VOLUNTARY ANNOUNCEMENT - Ascentage Pharma to Present Results from Multiple Clinical Studies of olverembatinib, lisaftoclax, APG-5918 at the 2025 American Society of Hematology (ASH) Annual Meeting, on Regulatory Filings	2025-11-04	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025 Share Issue/Capital Change	2025-10-08	English
INTERIM REPORT 2025 Interim / Quarterly Report H1 2025	2025-09-19	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025 Regulatory Filings	2025-09-04	English
ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 Interim / Quarterly Report H2 2025	2025-08-21	English
Voluntary Announcement - Global Registrational Phase III Study of Lisaftoclax for First-Line Treatment of HR-MDS Cleared by FDA and EMA Regulatory Filings	2025-08-18	English
NOTICE OF BOARD MEETING Regulatory Filings	2025-08-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025 Share Issue/Capital Change	2025-08-06	English
Next Day Disclosure Return Share Issue/Capital Change	2025-07-25	English
CLOSING OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE Share Issue/Capital Change	2025-07-25	English
PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE Share Issue/Capital Change	2025-07-15	English
Voluntary Announcement - Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA for Treatment of Adult CLL/SLL Patients Regulatory Filings	2025-07-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025 Share Issue/Capital Change	2025-07-07	English
FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME Share Issue/Capital Change	2025-06-27	English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST RESULTS FROM MULTIPLE CLINICAL STUDIES IN 2025 EUROPEAN HEMATOLOGY ASSOCIATION HYBRID CONGRESS (EHA) Regulatory Filings	2025-06-16	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025 Regulatory Filings	2025-06-05	English
VOLUNTARY ANNOUNCEMENT - Ascentage Pharma Presents Results from Two Clinical Studies at 2025 ASCO Annual Meeting, Including an Oral Presentation on Lisaftoclax Regulatory Filings	2025-05-23	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 19, 2025 Declaration of Voting Results & Voting Rights Announcements	2025-05-19	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025 Regulatory Filings	2025-05-08	English
SUPPLEMENTAL CIRCULAR - (1) PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME; (2) PROPOSED AMENDMENTS TO THE 2022 RSU SCHEME; (3) PROPOSED AMENDMENTS TO THE POST IPO SHARE OPTION SCHEME; (4) Proxy Solicitation & Information Statement	2025-04-30	English
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING AGM Information	2025-04-30	English
SECOND PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 19, 2025 Proxy Solicitation & Information Statement	2025-04-30	English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS RESULTS FROM FIVE PRECLINICAL STUDIES AT 2025 AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) ANNUAL MEETING, HIGHLIGHTING STRONG SYNERGISTIC EFFECTS Regulatory Filings	2025-04-28	English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT DATA FROM TWO CLINICAL STUDIES AT 2025 ASCO ANNUAL MEETING, INCLUDING ORAL PRESENTATION ON LISAFTOCLAX Regulatory Filings	2025-04-24	English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA ANNOUNCES INCLUSION OF LISAFTOCLAX AND OLVEREMBATINIB IN CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO) 2025 GUIDELINES Regulatory Filings	2025-04-21	English
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2025-04-16	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 19, 2025 Proxy Solicitation & Information Statement	2025-04-16	English
NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-04-16	English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-04-16	English
ANNUAL REPORT 2024 Annual Report FY 2024	2025-04-16	English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025 Regulatory Filings	2025-04-09	English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME Transaction in Own Shares	2025-04-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025 Regulatory Filings	2025-04-07	English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME Transaction in Own Shares	2025-03-31	English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 Earnings Release FY 2024	2025-03-27	English
VOLUNTARY ANNOUNCEMENT - Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 Regulatory Filings	2025-03-26	English
NOTICE OF BOARD MEETING Report Publication Announcement	2025-03-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025 Share Issue/Capital Change	2025-03-06	English
VOLUNTARY ANNOUNCEMENT - Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Regulatory Filings	2025-03-06	English
CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE Board/Management Information	2025-02-25	English
CLOSING OF THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION IN RELATION TO THE OFFERING OF AMERICAN DEPOSITARY SHARES Capital/Financing Update	2025-02-13	English
Next Day Disclosure Return Share Issue/Capital Change	2025-02-12	English
PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION IN RELATION TO THE OFFERING OF AMERICAN DEPOSITARY SHARES Share Issue/Capital Change	2025-02-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025 Regulatory Filings	2025-02-06	English
Company Information Sheet Governance Information	2025-02-02	English
CLOSING OF THE OFFERING OF AMERICAN DEPOSITARY SHARES Capital/Financing Update	2025-02-02	English
Next Day Disclosure Return Share Issue/Capital Change	2025-01-27	English
OFFERING OF AMERICAN DEPOSITARY SHARES AND ISSUANCE OF NEW ORDINARY SHARES UNDER THE GENERAL MANDATE Share Issue/Capital Change	2025-01-24	English
INSIDE INFORMATION AND OVERSEAS REGULATORY ANNOUNCEMENT - FURTHER UPDATES ON PROPOSED INITIAL PUBLIC OFFERING Share Issue/Capital Change	2025-01-21	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024 Regulatory Filings	2025-01-07	English
List of directors and their roles and functions Board/Management Information	2025-01-02	English
(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES Board/Management Information	2025-01-02	English

Filings by year

2026 26 filings
2025 58 filings
2024 50 filings
2023 49 filings
2022 60 filings
2021 88 filings
2020 57 filings
2019 20 filings